e-learning
resources
Paris 2018
Monday, 17.09.2018
COPD: from LABA/ICS to LABA/LAMA/ICS
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - Pharmacokinetic and pharmacodynamic interactions between components of extrafine formulation of BDP/FF/GB, a novel fixed-dose triple combination for asthma and COPD
M. Cella (Parma, Italy), L. Gheyle (Antwerp, Belgium), C. Garofalo (Parma, Italy), C. Beaudot (Cary, United States of America), G. Georges (Cary, United States of America)
Source:
International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Session:
COPD: from LABA/ICS to LABA/LAMA/ICS
Session type:
Oral Presentation
Number:
2132
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Cella (Parma, Italy), L. Gheyle (Antwerp, Belgium), C. Garofalo (Parma, Italy), C. Beaudot (Cary, United States of America), G. Georges (Cary, United States of America). Late Breaking Abstract - Pharmacokinetic and pharmacodynamic interactions between components of extrafine formulation of BDP/FF/GB, a novel fixed-dose triple combination for asthma and COPD. 2132
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Eliminating in-vitro drug-drug interactions in dual and triple fixed-dose combination therapies using a novel cosuspension metered dose inhaler platform
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
Comparative efficacy of umeclidinium/vilanterol versus LABA/LAMA therapies in COPD: A network meta-analysis
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Late Breaking Abstract - Comparing pneumonia risk in COPD patients initiating Fixed Dose Combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone
Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data
Year: 2021
Pharmacokinetic studies for the estimation of bioequivalence of two DPIs containing budesonide and formoterol
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Pharmacokinetic and pharmacodynamic evaluation after administration of beclomethasone dipropionate and formoterol fumarate as fixed or free metered-dose inhaler combination in adolescent asthma
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
Beclomethasone, formoterol and glycopyrronium: synergy of dual and triple combinations in an ex vivo model of COPD exacerbation
Source: Virtual Congress 2021 – Pharmacology of airway diseases: clinical and laboratory studies
Year: 2021
A novel biophysical simulation model predicts consistent lung delivery of QVA149, glycopyrronium and indacaterol via the Breezhaler
®
device
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014
Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta
2
-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Comparative in vitro performance of the new drug aclidinium in a novel multidose dry powder inhaler
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
In vitro validation of the use of a spacer with an extrafine beclomethasone/formoterol formulation
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Comparison of the pharmacokinetics and pharmacodynamics of once daily tiotropium Respimat® and tiotropium HandiHaler® in COPD patients
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013
Late Breaking Abstract - Impact of ICS/LABA and LABA/LAMA FDCs on lung function and exacerbation of COPD: a network meta-analysis
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018
Systemic exposure and lung bioavailability across two different dose strengths of CHF5993 a novel Triple pMDI
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
A single-dose double-blind study comparing efficacy of two dry powder inhalers containing budesonide and formoterol in asthmatic patients
Source: International Congress 2016 – Asthma management
Year: 2016
A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
Comparative safety-efficacy trial using three inhaler combinations in moderate persistent asthma
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010
A comparative study on systemic pharmacodynamic effects of two HFA formulations of salmeterol xinafoate, in healthy subjects
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept